31.68MMarket Cap-882P/E (TTM)
4.091High3.740Low115.91KVolume3.940Open3.910Pre Close458.23KTurnover2.18%Turnover RatioLossP/E (Static)8.12MShares4.55052wk High3.08P/B20.74MFloat Cap1.37052wk Low--Dividend TTM5.32MShs Float36.720Historical High--Div YieldTTM8.99%Amplitude1.370Historical Low3.953Avg Price1Lot Size
Lumos Pharma Stock Forum
I'm holding a little. hope gradually 🛫✌️
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
Lumos Pharma presented new analyses of its Phase 2 OraGrowtH212 trial at the ENDO 2024 meeting. The data reveals that oral LUM-201 significantly increased growth hormone (GH) secretion in children with moderate Pediatric Growth Hormone Deficiency (PGHD) over six months. The treatment restored GH levels to near-normal compared to healthy children, with lower GH exposure than tradit...
Lumos Pharma Inc: Outcome From End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial
AUSTIN, TX, April 18, 2024 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented...
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
✅ CDIO bucked the trend with a strategic 13.04% LONG MOVE and nimbly dipped 13.99% on the short side!
💥 HSCS is the short sensation, dropping a massive 57.85%!
💣 BIOL, LUMO, and BYU are making waves with short moves of 18.99%, 18.66%, and a whopping 27.34%, respectively!
See you all tomorrow AM for another rou...
No comment yet